Blockbuster drug
From Wikipedia, the free encyclopedia
A blockbuster drug is a drug generating more than $1 billion of revenue for its owner each year. The search for blockbusters has been the foundation of the R&D strategy adopted by big pharmaceutical companies, but this looks set to change. New advances in genomics, and the promise of personalized medicine, are likely to fragment the pharmaceutical market.
A recent report from Urch Publishing estimated that about one third of the pharma market by value is accounted for by blockbusters. About 100 products are blockbusters. The top seller was Lipitor a cholesterol-lowering medication marketed by Pfizer with sales of US$12,187 million
[edit] Leading blockbuster drugs
- atorvastatin (Lipitor) from Pfizer
- celecoxib (Celebrex) from Pfizer
- omeprazole (Losec/Prilosec) from AstraZeneca (2003 sales $2.6bn)
- esomeprazole (Nexium) from AstraZeneca (2003 sales $3.3bn)
- Fexofenadine (Telfast/Allegra) from Aventis (2004 sales $1.87bn)
- quetiapine (Seroquel) from AstraZeneca (2003 sales $1.5bn)
- metoprolol (Seloken/Toprol) from AstraZeneca (2003 sales $1.3bn)
- budesonide (Pulmicort/Rhinocort) from AstraZeneca (2003 sales $1.3bn, plus some fraction of the $0.6bn sales of Symbicort)
[edit] Further reading
Pharmaceutical Market Trends, 2006-2010, from Urch Publishing [1]
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
